A randomized, double-blind study published recently in The Lancet showed that men on active surveillance for low-risk prostate cancer (PCa) who received the 5α-reductase inhibitor dutasteride for three years had a significant 38% decreased risk of PCa progression compared with men who took placebo. The investigators concluded that their findings “show that dutasteride could be a beneficial adjunct to active surveillance for men with low-risk prostate cancer, delaying their time to pathological progression and initiation of primary therapy.”
Renal & Urology News would like to ask its urologist readers the following question.
In light of the study’s findings, would you consider prescribing dutasteride to men with low-risk prostate cancer (PCa) to reduce their risk of PCa progression?
Leave a comment below to explain your choice.